Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone for Home IV Staphylococcal Infections
NCT04141787Phase 4Unknown
- Sponsor
- Island Health
- Start
- Jul 2019
- Primary completion
- Jul 2023
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ceftriaxone in staphylococcal infection (2 arms), sponsored by Island Health. Primary endpoint: Clinical cure rate of deep-seated methicillin sensitive Staphylococcal infections at 6 months. Status: unknown.
02
Drugs
ceftriaxone
03
Conditions
staphylococcal infection
Beyond the preview
Go deeper on NCT04141787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141787.